ClinicalTrials.gg
Active, not recruitingNCT05528510ASTROUpdated Nov 4, 2026Results posted

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 236 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
8th of 28
418 · median 205
Started
2022
with 1 other
Phase 3
15 of 43
2 open now
Primary completion
2024-04
later than 2 of 20 live
Registered
29th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 in phase 3, reaches primary completion later than 2 of the 20 other live ones, and was the 29th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • Guselkumab
  • Colitis, Ulcerative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form
  • 18 years of age or older
  • Documented diagnosis of ulcerative colitis (UC) at least 12 weeks prior to screening
  • Moderately to severely active UC as per the modified Mayo score
  • Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease
  • Surgery within 8 weeks before screening or planned surgery during the study that may confound the evaluation of benefit from study intervention
  • Receiving prohibited medications and treatments
  • UC limited to the rectum only
  • Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) corona virus disease (COVID-19) infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive guselkumab (Dose 1) subcutaneous (SC) injection followed by guselkumab (Dose 2) SC injection.

    Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab (Dose 1) SC injection followed by guselkumab (Dose 3) SC injection.

    Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 3

  • Placebo comparator
    Group 3: Placebo

    Participants will receive matching placebo SC injection.

    Other: Placebo

Interventions

  • Guselkumab (Dose 1) will be administered as SC injection.

  • Guselkumab (Dose 2) will be administered as SC injection.

  • Guselkumab (Dose 3) will be administered as SC injection.

  • OtherPlacebo

    Placebo will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission at Week 12

    Percentage of participants in clinical remission at Week 12 was reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants in Symptomatic Remission at Week 12

    Percentage of participants in symptomatic remission at Week 12 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.

    Time frame: Week 12

  2. Percentage of Participants With Endoscopic Improvement at Week 12

    Percentage of participants with endoscopic improvement at Week 12 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

    Time frame: Week 12

  3. Percentage of Participants in Clinical Response at Week 12

    Percentage of participants in clinical response at Week 12 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

    Time frame: Week 12

  4. Percentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 12

    Percentage of participants with histologic-endoscopic mucosal improvement at Week 12 was reported. Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

    Time frame: Week 12

  5. Percentage of Participants in Clinical Remission at Week 24

    Percentage of participants in clinical remission at Week 24 was reported. Clinical remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

    Time frame: Week 24

  6. Percentage of Participants in Symptomatic Remission at Week 24

    Percentage of participants in symptomatic remission at Week 24 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.

    Time frame: Week 24

  7. Percentage of Participants With Endoscopic Improvement at Week 24

    Percentage of participants with endoscopic improvement at Week 24 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

    Time frame: Week 24

  8. Percentage of Participants in Clinical Response at Week 24

    Percentage of participants in clinical response at Week 24 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by \>= 30% and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

    Time frame: Week 24

07

Results

Posted Dec 9, 2025

Participant flow

Results are currently reported up to the primary completion date (02-Apr-2024). Results of remaining duration will be posted upon study completion.

Participant flow — Overall Study
MilestonePlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Started139139140
Participants who started rescue medication522723
Completed131136136
Not completed834
Withdrew: Death100
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject413
Withdrew: Other221

Outcome measures

PrimaryPercentage of Participants in Clinical Remission at Week 12

Percentage of participants in clinical remission at Week 12 was reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission at Week 12
Percentage of participantsPlaceboCombined Guselkumab 400 mg
Percentage of Participants in Clinical Remission at Week 126.5 (2.4 to 10.6)27.6 (22.4 to 32.8)
Statistical analysis
  • Placebo · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 21.1 · 95% CI 14.5 to 27.6Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants in Symptomatic Remission at Week 12

Percentage of participants in symptomatic remission at Week 12 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Symptomatic Remission at Week 12
Percentage of participantsPlaceboCombined Guselkumab 400 mg
Percentage of Participants in Symptomatic Remission at Week 1220.9 (14.1 to 27.6)51.3 (45.4 to 57.1)
Statistical analysis
  • Placebo · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 30.4 · 95% CI 21.6 to 39.2Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants With Endoscopic Improvement at Week 12

Percentage of participants with endoscopic improvement at Week 12 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Improvement at Week 12
Percentage of participantsPlaceboCombined Guselkumab 400 mg
Percentage of Participants With Endoscopic Improvement at Week 1212.9 (7.4 to 18.5)37.3 (31.6 to 42.9)
Statistical analysis
  • Placebo · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 24.3 · 95% CI 16.6 to 31.9Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants in Clinical Response at Week 12

Percentage of participants in clinical response at Week 12 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Response at Week 12
Percentage of participantsPlaceboCombined Guselkumab 400 mg
Percentage of Participants in Clinical Response at Week 1234.5 (26.6 to 42.4)65.6 (60.0 to 71.2)
Statistical analysis
  • Placebo · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 31 · 95% CI 21.6 to 40.5Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 12

Percentage of participants with histologic-endoscopic mucosal improvement at Week 12 was reported. Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 12
Percentage of participantsPlaceboCombined Guselkumab 400 mg
Percentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 1210.8 (5.6 to 15.9)30.5 (25.1 to 35.9)
Statistical analysis
  • Placebo · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 19.6 · 95% CI 12.4 to 26.9Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants in Clinical Remission at Week 24

Percentage of participants in clinical remission at Week 24 was reported. Clinical remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission at Week 24
Percentage of participantsPlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Percentage of Participants in Clinical Remission at Week 249.4 (4.5 to 14.2)35.3 (27.3 to 43.2)36.4 (28.5 to 44.4)
Statistical analysis
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 100 mg q8w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 25.9 · 95% CI 16.7 to 35.1Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 200 mg q4w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 27 · 95% CI 17.9 to 36.2Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants in Symptomatic Remission at Week 24

Percentage of participants in symptomatic remission at Week 24 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants in Symptomatic Remission at Week 24
Percentage of participantsPlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Percentage of Participants in Symptomatic Remission at Week 2425.2 (18.0 to 32.4)54.7 (46.4 to 63.0)50.0 (41.7 to 58.3)
Statistical analysis
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 100 mg q8w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 29.5 · 95% CI 18.5 to 40.5Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 200 mg q4w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 24.8 · 95% CI 14.3 to 35.3Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants With Endoscopic Improvement at Week 24

Percentage of participants with endoscopic improvement at Week 24 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Improvement at Week 24
Percentage of participantsPlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Percentage of Participants With Endoscopic Improvement at Week 2412.2 (6.8 to 17.7)40.3 (32.1 to 48.4)45.0 (36.8 to 53.2)
Statistical analysis
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 100 mg q8w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 28.1 · 95% CI 18.5 to 37.6Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 200 mg q4w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 32.7 · 95% CI 23.1 to 42.3Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
SecondaryPercentage of Participants in Clinical Response at Week 24

Percentage of participants in clinical response at Week 24 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by \>= 30% and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Response at Week 24
Percentage of participantsPlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Percentage of Participants in Clinical Response at Week 2430.9 (23.3 to 38.6)63.3 (55.3 to 71.3)61.4 (53.4 to 69.5)
Statistical analysis
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 100 mg q8w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 32.4 · 95% CI 21.3 to 43.4Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).
  • Placebo vs Guselkumab 400 mg q4w - Guselkumab 200 mg q4w · Mantel Haenszel · p = <0.001 · Adjusted treatment difference: 30.5 · 95% CI 20.0 to 41.0Stratification was by Androgen Deprivation Therapy for Intermediate-Risk status (Yes/No) and Mayo endoscopy subscore at baseline(moderate or severe).

Adverse events

Collected over All-cause mortality: From screening (-8 weeks) up to Week 24; Serious adverse events (SAEs) and Other AEs: From Week 0 up to Week 24. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Before Rescue Medication)1/139 (0.7%)17/139 (12.2%)48/139 (34.5%)
Placebo - Guselkumab (After Rescue Medication)0/52 (0%)1/52 (1.9%)5/52 (9.6%)
Guselkumab 400 mg q4w - Guselkumab 100 mg q8w0/139 (0%)5/139 (3.6%)47/139 (33.8%)
Guselkumab 400 mg q4w - Guselkumab 200 mg q4w0/140 (0%)6/140 (4.3%)39/140 (27.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlacebo (Before Rescue Medication)Placebo - Guselkumab (After Rescue Medication)Guselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Colitis UlcerativeGastrointestinal disorders11/1391/522/1392/140
AnaemiaBlood and lymphatic system disorders2/1390/520/1390/140
AppendicitisInfections and infestations0/1390/520/1392/140
Ventricular ExtrasystolesCardiac disorders0/1390/521/1390/140
Colon DysplasiaGastrointestinal disorders1/1390/520/1390/140
Frequent Bowel MovementsGastrointestinal disorders1/1390/520/1390/140
PyrexiaGeneral disorders1/1390/520/1390/140
GastroenteritisInfections and infestations0/1390/521/1390/140
PneumoniaInfections and infestations1/1390/520/1390/140
Humerus FractureInjury, poisoning and procedural complications1/1390/520/1390/140
Most frequent other events
Most frequent other events
EventPlacebo (Before Rescue Medication)Placebo - Guselkumab (After Rescue Medication)Guselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4w
Colitis UlcerativeGastrointestinal disorders19/1391/5212/1397/140
ArthralgiaMusculoskeletal and connective tissue disorders3/1390/5211/1397/140
Upper Respiratory Tract InfectionInfections and infestations9/1390/5210/1395/140
AnaemiaBlood and lymphatic system disorders8/1392/525/1395/140
NasopharyngitisInfections and infestations8/1390/525/1394/140
HeadacheNervous system disorders3/1390/527/1395/140
AlopeciaSkin and subcutaneous tissue disorders1/1390/526/1392/140
Injection Site ErythemaGeneral disorders1/1391/524/1396/140
Abdominal PainGastrointestinal disorders5/1390/522/1392/140
Covid-19Infections and infestations5/1391/525/1392/140

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
Mean39.5 ± 13.5842.1 ± 14.5943.6 ± 14.2741.7 ± 14.22
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
Female496053162
Male907987256
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
Hispanic or Latino23302679
Not Hispanic or Latino112102112326
Unknown or Not Reported47213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
American Indian or Alaska Native0404
Asian404140121
Native Hawaiian or Other Pacific Islander0000
Black or African American16613
White948591270
More than one race1113
Unknown or Not Reported3227
AgeCategorical
AgeCategorical(Participants)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
Adults (18-64 years)131123131385
65 years and over816933
Region of Enrollment
Region of Enrollment(Participants)PlaceboGuselkumab 400 mg q4w - Guselkumab 100 mg q8wGuselkumab 400 mg q4w - Guselkumab 200 mg q4wTotal
ARGENTINA44311
AUSTRALIA2237
BELGIUM0202
BRAZIL17181954
BULGARIA1214
CANADA1001
CHINA19121647
CZECH REPUBLIC45312
FRANCE36312
GERMANY2125
HUNGARY3148
INDIA32813
ISRAEL2226
JAPAN7151032
JORDAN96621
MALAYSIA2327
MEXICO15612
NEW ZEALAND3104
POLAND31283493
SLOVAKIA2002
SOUTH KOREA76215
SPAIN5106
TAIWAN0314
TURKEY1427
UNITED STATES10101333
08

Study locations

236 sites

Showing the first 100 of 236 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jorgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L; ASTRO Study Group. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 Apr;11(4):284-298. doi: 10.1016/S2468-1253(25)00322-X. Epub 2026 Jan 13. PubMed 41544637 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2024, 18 months.

Results were first posted in Dec 2025, 1 year 8 months after primary completion. A results delay was requested in Apr 2025.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 18 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Sep 6, 2022
StartActual
Sep 13, 2022
Primary completionActual
Apr 2, 2024
CompletionEst.
Oct 6, 2028
Results delay requested
Apr 1, 2025
Results first posted
Dec 9, 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05528510
Responsible party
Sponsor
First posted
Sep 6, 2022
Start date
Sep 13, 2022
Primary completion
Apr 2, 2024
Completion
Oct 6, 2028 (estimated)
Results posted
Dec 9, 2025
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion